These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 25520081)
21. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. Reijnders JG; Pas SD; Schutten M; de Man RA; Janssen HL J Hepatol; 2009 Apr; 50(4):674-83. PubMed ID: 19231002 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288 [TBL] [Abstract][Full Text] [Related]
23. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease. Chen FW; Coyle L; Jones BE; Pattullo V Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150 [TBL] [Abstract][Full Text] [Related]
24. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L; N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238 [TBL] [Abstract][Full Text] [Related]
26. Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance. Lee S; Ahn SH; Jung KS; Kim DY; Kim BK; Kim SU; Baatarkhuu O; Ku HJ; Han K; Park JY J Viral Hepat; 2017 Feb; 24(2):141-147. PubMed ID: 27766731 [TBL] [Abstract][Full Text] [Related]
27. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Wong DK; Yuen MF; Ngai VW; Fung J; Lai CL Antivir Ther; 2006; 11(7):909-16. PubMed ID: 17302253 [TBL] [Abstract][Full Text] [Related]
28. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy. Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649 [TBL] [Abstract][Full Text] [Related]
29. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466 [TBL] [Abstract][Full Text] [Related]
30. Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma. Tsai HW; Lin YJ; Wu HC; Chang TT; Wu IC; Cheng PN; Yen CJ; Chan SH; Huang W; Su IJ Oncotarget; 2016 May; 7(19):27724-34. PubMed ID: 27027237 [TBL] [Abstract][Full Text] [Related]
31. Effects of radiofrequency ablation combined with transarterial chemoembolization and antiviral therapy on the prognosis and quality of life in primary chronic HBV-related liver cancer. Lu B; Zhu L; Wang X; Zhong L; Cheng Y; Fan J; Yu L J BUON; 2019; 24(5):1979-1984. PubMed ID: 31786864 [TBL] [Abstract][Full Text] [Related]
32. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Lao XM; Luo G; Ye LT; Luo C; Shi M; Wang D; Guo R; Chen M; Li S; Lin X; Yuan Y Liver Int; 2013 Apr; 33(4):595-604. PubMed ID: 23402625 [TBL] [Abstract][Full Text] [Related]
33. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Faria LC; Gigou M; Roque-Afonso AM; Sebagh M; Roche B; Fallot G; Ferrari TC; Guettier C; Dussaix E; Castaing D; Brechot C; Samuel D Gastroenterology; 2008 Jun; 134(7):1890-9; quiz 2155. PubMed ID: 18424269 [TBL] [Abstract][Full Text] [Related]
34. Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis. An J; Shim JH; Kim SO; Choi J; Kim SW; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ J Med Virol; 2016 Sep; 88(9):1576-86. PubMed ID: 26945543 [TBL] [Abstract][Full Text] [Related]
35. [Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48]. Ma H; Ren JB; Li HY; Wang Y; Wang RL; Liang L; Sun SJ; Jia JD Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun; 21(2):102-4. PubMed ID: 17653304 [TBL] [Abstract][Full Text] [Related]
36. Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues. Wong GL; Chan HL; Lo AO; Chan HY; Tse CH; Chim AM; Wong VW Antivir Ther; 2013; 18(8):979-86. PubMed ID: 23744529 [TBL] [Abstract][Full Text] [Related]
37. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Chan HL; Wong VW; Tse AM; Tse CH; Chim AM; Chan HY; Wong GL; Sung JJ Clin Gastroenterol Hepatol; 2007 Dec; 5(12):1462-8. PubMed ID: 18054753 [TBL] [Abstract][Full Text] [Related]
38. Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis. Xu Y; Wu XN; Shi YW; Wei W; Yang AT; Sun YM; Zhao WS; You H Chin Med J (Engl); 2015 Jul; 128(14):1867-72. PubMed ID: 26168824 [TBL] [Abstract][Full Text] [Related]
39. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Nagamatsu H; Itano S; Nagaoka S; Akiyoshi J; Matsugaki S; Kurogi J; Tajiri N; Yamasaki S; Koga H; Torimura T; Kumashiro R; Sata M Am J Gastroenterol; 2004 Dec; 99(12):2369-75. PubMed ID: 15571585 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Liaw YF; Raptopoulou-Gigi M; Cheinquer H; Sarin SK; Tanwandee T; Leung N; Peng CY; Myers RP; Brown RS; Jeffers L; Tsai N; Bialkowska J; Tang S; Beebe S; Cooney E Hepatology; 2011 Jul; 54(1):91-100. PubMed ID: 21503940 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]